Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.

NCT03808805 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT03808805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03808805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.
Lead sponsor
University Hospital, Brest
Phase
Phase 3
Overall status
Completed
Start date
April 16, 2019
Completion date
August 22, 2024
Enrollment
63 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

aquagenic pruritus, myeloproliferative disorder